IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.048
AS - Asia 1.075
EU - Europa 850
SA - Sud America 223
Continente sconosciuto - Info sul continente non disponibili 147
AF - Africa 26
OC - Oceania 3
Totale 4.372
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.955
IT - Italia 529
SG - Singapore 492
CN - Cina 249
BR - Brasile 169
DE - Germania 102
IN - India 97
VN - Vietnam 88
GB - Regno Unito 73
CA - Canada 55
HK - Hong Kong 48
SE - Svezia 35
FI - Finlandia 34
BD - Bangladesh 23
NL - Olanda 20
MX - Messico 14
ID - Indonesia 13
AR - Argentina 12
FR - Francia 11
ZA - Sudafrica 11
EC - Ecuador 10
JP - Giappone 10
RU - Federazione Russa 10
VE - Venezuela 8
CR - Costa Rica 7
ES - Italia 7
EU - Europa 7
AT - Austria 6
CO - Colombia 6
IQ - Iraq 6
PY - Paraguay 6
UZ - Uzbekistan 6
CL - Cile 5
CZ - Repubblica Ceca 5
IL - Israele 5
KE - Kenya 5
PK - Pakistan 5
TR - Turchia 5
UA - Ucraina 5
JO - Giordania 4
AU - Australia 3
CH - Svizzera 3
EG - Egitto 3
GT - Guatemala 3
JM - Giamaica 3
LB - Libano 3
NP - Nepal 3
PE - Perù 3
PL - Polonia 3
SC - Seychelles 3
AZ - Azerbaigian 2
ET - Etiopia 2
HN - Honduras 2
IR - Iran 2
LT - Lituania 2
MA - Marocco 2
NI - Nicaragua 2
OM - Oman 2
PR - Porto Rico 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
IE - Irlanda 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LV - Lettonia 1
MM - Myanmar 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SV - El Salvador 1
TH - Thailandia 1
Totale 4.232
Salva come PNG Salva come JPEG
Città #
San Jose 365
Singapore 217
Ashburn 209
Chandler 152
Santa Clara 94
Dallas 79
Munich 71
Council Bluffs 70
Bengaluru 66
Hefei 66
Beijing 58
Chicago 57
Milan 51
London 50
Catanzaro 46
Princeton 45
Hong Kong 44
Lawrence 44
Ho Chi Minh City 31
Phoenix 30
Naples 27
Los Angeles 24
Rome 24
Hanoi 23
Turku 22
New York 21
Wilmington 18
São Paulo 16
Parma 14
Des Moines 13
Ottawa 13
Brooklyn 12
Carbonia 12
Helsinki 12
Montreal 12
Boardman 9
Boston 9
Cosenza 8
Ercolano 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Aversa 7
Bologna 7
San José 7
Catania 6
Columbus 6
Dhaka 6
Manchester 6
Melito di Porto Salvo 6
Orem 6
Reggio Calabria 6
Shanghai 6
Stockholm 6
Tashkent 6
Buffalo 5
Charlotte 5
Chennai 5
Denver 5
Frankfurt am Main 5
Guangzhou 5
Mexico City 5
Nairobi 5
Seattle 5
Settingiano 5
The Dalles 5
Tokyo 5
Amman 4
Brescia 4
Can Tho 4
Da Nang 4
Decollatura 4
Haiphong 4
Hanover 4
Jakarta 4
Jiaxing 4
Johannesburg 4
Mountain View 4
New Delhi 4
Pune 4
Redmond 4
Rio de Janeiro 4
San Francisco 4
Thái Bình 4
Acquaviva delle Fonti 3
Ahmedabad 3
Atlanta 3
Bari 3
Belo Horizonte 3
Berlin 3
Biên Hòa 3
Cape Town 3
Castrovillari 3
Florence 3
Guatemala City 3
Guayaquil 3
Kingston 3
Las Vegas 3
Madrid 3
Totale 2.427
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 154
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 129
miR-22 suppresses DNA ligase III addiction in multiple myeloma 116
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 106
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 101
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 98
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 97
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 91
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 88
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 84
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 84
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 82
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 82
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 81
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 81
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 80
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 80
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 76
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 75
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 74
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 74
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 73
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 71
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 69
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 67
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 67
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 66
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 65
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 65
Mir-221/222 are promising targets for innovative anticancer therapy 65
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 63
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 63
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 62
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 62
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 62
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 62
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 62
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 60
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 59
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 58
Mmrf-commpass data integration and analysis for identifying prognostic markers 56
Integration of DNA Microarray with Clinical and Genomic Data 56
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 54
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 54
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 53
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 52
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 51
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 50
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 46
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 44
The potential role of miRNAs in multiple myeloma therapy 43
null 43
The potential role of miRNAs in multiple myeloma therapy 41
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 41
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 40
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 40
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 37
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 36
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 33
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 32
null 31
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 29
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 29
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 28
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 27
UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager 21
Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase 20
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 16
PARP1 trapping activates cGAS-STING pathway to induce immunogenic cell death in multiple myeloma 16
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 16
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 15
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 13
Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis 10
Totale 4.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.352
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.352
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022175 0 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/20261.761 111 184 168 227 196 84 244 83 211 153 69 31
2026/2027504 21 103 237 143 0 0 0 0 0 0 0 0
Totale 4.372